{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002686","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.837449+00:00","generated_at":"2026-06-07T02:19:22.794928+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Athira reports $147.4M cash, completes LIFT-AD enrollment, CMO Moebius retiring","bullets":["Preliminary cash, cash equivalents, and investments of ~$147.4M as of Dec 31, 2023.","Completed enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for Alzheimer's; topline data expected H2 2024.","Plans to initiate first-in-human studies of ATH-1105 for ALS in H1 2024.","CMO Hans Moebius retired effective Jan 5, 2024; will serve as Senior Scientific Advisor through March 31 transition period.","Over 60 patients continue fosgonimeton treatment beyond 18 months in open-label extension."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002686","json":"https://secwatch.observer/filing/0000950170-24-002686.json","markdown":"https://secwatch.observer/filing/0000950170-24-002686.md","text":"https://secwatch.observer/filing/0000950170-24-002686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/0000950170-24-002686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/atha-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:19:22.794928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87fe14254e","claim":"Hans Moebius changed role as Senior Scientific Advisor at LeonaBio, Inc..","evidence_excerpt":"Dr. Moebius voluntarily resigned his position as CMO effective January 5, 2024, and will continue employment on an at-will basis for a transition period ending March 31, 2024 (the “Transition Period”). During the Transition Period, Dr. Moebius will serve as a full-time employee in the role of Senior Scientific Advisor reporting to the Company’s Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/0000950170-24-002686-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Role","value":"Senior Scientific Advisor"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}